Overview

Efficacy and Tolerance of 4 Weeks of Tedizolid in Prosthetic Joint Infections Treated With Implant Removal

Status:
Not yet recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of 4 weeks of 200 mg/24h of tedizolid for prosthetic join infections caused by tedizolid susceptible microorganisms treated with implant removal in one or two stages at 6 months of followup after stopping tedizolid treatment.

Phase:

Phase 4

Details

Lead Sponsor:

Fundacion Clinic per a la Recerca Biomédica

Treatments:

Tedizolid phosphate
Torezolid
Torezolid phosphate